Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
26 août 2022 16h30 HE
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (August 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
02 août 2022 06h00 HE
|
Allarity Therapeutics, Inc.
New strategy aligns with ongoing shift in oncology standard-of-caretowards combination therapies Combination therapy focus expected to improve the Company’s future funding and commercial...
Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.
11 juil. 2022 07h00 HE
|
Allarity Therapeutics, Inc.
Interim CEO James G. Cullem, J.D. and Co-Founder Thomas Jensen also joining the Board Press ReleaseCambridge, MA, U.S.A. (July 11, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the...
Allarity Therapeutics Announces Executive Leadership Transition
29 juin 2022 16h01 HE
|
Allarity Therapeutics, Inc.
Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,Joan Y. Brown, CPA, to Interim Chief Financial Officer Press release Cambridge, MA, U.S.A. (June 29, 2022) — Allarity...
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.
15 juin 2022 09h25 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (June 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Reports First Quarter 2022 Financial Results
27 mai 2022 17h37 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (May 27, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
18 mai 2022 17h30 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (May 18, 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity Therapeutics Reports Fourth Quarter and Full...
Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
16 mai 2022 19h40 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (May 16, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
22 avr. 2022 17h00 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (April 22, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Provides Update on Dovitinib Program
15 mars 2022 08h32 HE
|
Allarity Therapeutics, Inc.
FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...